Status:
COMPLETED
Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures
Lead Sponsor:
UCB Pharma
Conditions:
Epilepsies, Partial
Eligibility:
All Genders
16+ years
Brief Summary
SP942 is a non-interventional post-authorization safety study (PASS) to evaluate the long-term safety and tolerability of Vimpat® (Lacosamide, LCM) as add-on treatment in patients with Epilepsy 16 yea...
Eligibility Criteria
Inclusion
- This study includes any subject 16 years or older who has an Epilepsy diagnosis with Partial-Onset Seizures; and whose Seizure activity is uncontrolled on current therapy
- Patients who are prescribed Vimpat or any other add-on Antiepileptic Drug (AED) may be included in the study
- The initiation of an add-on AED therapy can not be more than 2 days before the patient's start of the study
Exclusion
- N/A
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
1005 Patients enrolled
Trial Details
Trial ID
NCT00771927
Start Date
October 1 2008
End Date
March 1 2012
Last Update
October 27 2014
Active Locations (62)
Enter a location and click search to find clinical trials sorted by distance.
1
Bron, France
2
Dijon, France
3
La Tronche, France
4
Montpellier, France